Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing process to standardize lovastatin in Cholestin cited by agency.

This article was originally published in The Tan Sheet

Executive Summary

CHOLESTIN MANUFACTURING PROCESS INVOLVING STANDARDIZED LOVASTATIN content is cited by FDA to support its conclusion that Pharmanex intends primarily to manufacture lovastatin. Evidence the company is manufacturing the drug "consists of material indicating that Pharmanex purposely designed a manufacturing process intended consistently to maximize and standardize levels of lovastatin in Cholestin," FDA maintains. The agency's arguments were made in a May 20 letter to Pharmanex.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel